Related Experiment Video
Updated: Jul 25, 2025
Advanced 3D Liver Models for In vitro Genotoxicity Testing Following Long-Term Nanomaterial Exposure
Published on: June 5, 2020
Protective effects of resveratrol against fumonisin B1-induced liver toxicity in mice
Rıza Yalçın1, Asım Kart1, Özlem Özmen2
11Burdur Mehmet Akif Ersoy University, Faculty of Veterinary Medicine, Department of Pharmacology and Toxicology, Burdur, Turkey.
Abstract:
The aim of this study was to investigate the effects of resveratrol against fumonisin B1 (FB1)-induced liver toxicity, as, to the best of our knowledge, these effects have not been investigated yet, even though the toxic effects and mechanisms of FB1 and the antioxidative effects of resveratrol are well known. 40 BALB/c mice were divided into control, FB1, resveratrol, and FB1+resveratrol groups. Control received saline for 14 days. The FB1 group received 2.25 mg/kg FB1 every other day for 14 days. The resveratrol group received 10 mg/kg resveratrol for 14 days. The FB1+resveratrol group received 2.25 mg/kg FB1 every other day and 10 mg/kg resveratrol every day for 14 days. All administrations were peritoneal. Alanine aminotransferase (ALT), aspartate aminotransferase (AST), total sialic acid (TSA) levels were analysed in serum samples, while total antioxidant status (TAS) and total oxidant status (TOS) were measured in the liver. Additionally, the liver tissue was examined for histopathological changes. AST, ALT, and TSA were significantly higher in the FB1 group than control. Resveratrol countered FB1 effects for all parameters, including TOS and TAS. Liver histology showed FB1-induced hyperaemia, infiltrations, and megalokaryosis in some hepatocytes. No pathological findings were detected in the control, resveratrol, or FB1+resveratrol group. Our findings confirm resveratrol's protective effect against liver damage and oxidative stress caused by FB1. In addition, they suggest that increased serum TSA levels can be used as a biomarker of FB1-induced hepatotoxicity.
Insights
Resveratrol protects against fumonisin B1 (FB1) liver toxicity and oxidative stress. Increased total sialic acid (TSA) indicates FB1-induced liver damage, suggesting TSA as a potential biomarker.
Area of Science:
- Toxicology
- Hepatology
- Natural Product Chemistry
Background:
- Fumonisin B1 (FB1) is a mycotoxin causing liver toxicity.
- Resveratrol exhibits known antioxidant properties.
- The protective effects of resveratrol against FB1-induced hepatotoxicity are not well-documented.
Purpose of the Study:
- To investigate resveratrol's efficacy in mitigating FB1-induced liver damage.
- To evaluate FB1-induced oxidative stress markers and histopathological changes.
- To explore total sialic acid (TSA) as a potential biomarker for FB1 hepatotoxicity.
Main Methods:
- BALB/c mice were administered FB1 and/or resveratrol peritoneally for 14 days.
- Serum biochemical markers (AST, ALT, TSA) and liver oxidative stress markers (TAS, TOS) were analyzed.
- Liver tissues were examined for histopathological alterations.
Main Results:
- FB1 significantly elevated serum AST, ALT, and TSA levels, and liver TOS, while decreasing TAS.
- Resveratrol administration counteracted FB1-induced changes in all measured biochemical and oxidative stress parameters.
- Histopathological examination revealed FB1-induced liver damage, which was prevented by resveratrol.
Conclusions:
- Resveratrol demonstrates significant protective effects against FB1-induced hepatotoxicity and oxidative stress.
- Elevated serum TSA levels can serve as a reliable biomarker for FB1-induced liver injury.
- This study highlights resveratrol as a potential therapeutic agent against mycotoxin-induced liver damage.
